Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia

被引：0
|
作者：
Hillmen, P.
Skotnicki, A.
Robak, T.
Jaksic, B.
Sirard, C.
Mayer, J.
机构：
[1] Leeds Gen Infirm, Leeds, W Yorkshire, England
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Kopernik Mem Hosp, Lodz, Poland
[4] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[5] GENZYME, Cambridge, MA USA
[6] Univ Hosp Brno, Brno, Czech Republic
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0127
引用
收藏
页码：45 / 46
页数：2
相关论文
共 50 条
  • [1] Alemtuzumab (CAMPATH®,MABCAMPATH®) has superior progression free survival (PFS) vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, Peter
    Skotnicki, Aleksander
    Robak, Tadeusz
    Jaksic, Branimir
    Sirard, Cynthia
    Mayer, Jiri
    BLOOD, 2006, 108 (11) : 93A - 93A
  • [2] Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Robak, T
    Skotnicki, AB
    Mayer, J
    Vukovic, V
    Weitman, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 573S - 573S
  • [3] Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 339S - 339S
  • [4] Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Dmoszynska, A.
    Fetni, R.
    Wang, Y.
    Belkaci, M.
    Sirard, C.
    Goldberg, M.
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 361S - 361S
  • [5] Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.
    Hillmen, P
    Skotnicki, AB
    Robak, T
    Mayer, J
    Jaksic, B
    Vukovic, V
    Weitman, S
    BLOOD, 2004, 104 (11) : 687A - 687A
  • [6] Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (CAMPATH®, MABCAMPATH®) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307).
    Skotnicki, AB
    Robak, T
    Mayer, J
    Craig, A
    Weitman, S
    BLOOD, 2003, 102 (11) : 439A - 439A
  • [7] Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia
    Mabed, M
    Aref, S
    Fouda, M
    El-Sharawy, S
    LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2029 - 2035
  • [8] Front-Line Therapy for Chronic Lymphocytic Leukemia
    Desai, Sheetal
    Pinilla-Ibarz, Javier
    CANCER CONTROL, 2012, 19 (01) : 26 - 36
  • [9] FRONT-LINE THERAPY WITH CHLORAMBUCIL PLUS RITUXIMAB IN ELDERLY AND/OR UNFIT PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA
    Innocenti, I.
    Tarnani, M.
    Vannata, B.
    De Padua, L.
    Santini, F.
    Marietti, S.
    Za, T.
    Bellesi, S.
    Autore, F.
    Chiusolo, P.
    Sora, F.
    Sica, S.
    Leone, G.
    Laurenti, L.
    HAEMATOLOGICA, 2012, 97 : 523 - 524
  • [10] Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
    Laurenti, Luca
    Vannata, Barbara
    Innocenti, Idanna
    Autore, Francesco
    Santini, Francesco
    Piccirillo, Nicola
    Za, Tommaso
    Bellesi, Silvia
    Marietti, Sara
    Sica, Simona
    Efremov, Dimitar G.
    Leone, Giuseppe
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2013, 5 (01):
12345